Clinical Trial

Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

Study acronym: NeoADT-TULSA
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound. This clinical trial explores if adding drug therapy with Degarelix before TULSA has the potential to improve further the effectiveness of TULSA in the treatment of localized prostate cancer, especially for patients with more aggressive diseases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-14; most recent amendment 2025-02-13.
Status change: Recruiting → Active, Not Recruiting 2025-02-13
Status change: Not Yet Recruiting → Recruiting 2024-04-24
Trial Details
NCT Number NCT05917860
Lead Sponsor Turku University Hospital
Conditions Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer
Enrollment 15 participants
Start Date 2023-07-18
Primary Completion 2026-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17